Anzeige
Mehr »
Freitag, 24.10.2025 - Börsentäglich über 12.000 News
Das Comeback des Goldrauschs - diesmal ausgelöst durch eine Währungskrise
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2PYWB | ISIN: US09203E1055 | Ticker-Symbol:
NASDAQ
23.10.25 | 21:58
3,890 US-Dollar
0,00 % 0,000
Branche
Biotechnologie
Aktienmarkt
Sonstige
1-Jahres-Chart
BLACK DIAMOND THERAPEUTICS INC Chart 1 Jahr
5-Tage-Chart
BLACK DIAMOND THERAPEUTICS INC 5-Tage-Chart

Aktuelle News zur BLACK DIAMOND THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
MiBDTX vs. ORIC: Which Oncology Focused Biotech Stock Is a Better Pick Now?4
15.10.Can NSCLC Drug Silevertinib Drive Sustainable Growth for BDTX?3
30.09.Freedom Capital Markets startet Coverage für Black Diamond Therapeutics mit "Buy"-Rating12
30.09.Black Diamond Therapeutics stock initiated with Buy rating at Freedom Capital1
25.09.Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?1
23.09.BDTX vs. Cullinan Therapeutic: Which EGFR Challenger Is the Better Buy?2
12.09.Is BDTX's Cash balance Enough to Successfully Develop Its NSCLC Drug?2
BLACK DIAMOND THERAPEUTICS Aktie jetzt für 0€ handeln
05.09.BDTX Stock Surges 51.1% in Six Months: Is There More Room for Growth?2
04.09.Black Diamond Therapeutics stock initiated with Buy rating at Guggenheim2
11.08.H.C. Wainwright lowers Black Diamond Therapeutics stock price target on delayed launch43
07.08.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update237Enrollment completed for the Phase 2 trial of silevertinib (BDTX-1535) in 1L patients with non-classical EGFRm NSCLC (n=43); ORR and preliminary DOR data on track for Q4 2025Exploring partnership...
► Artikel lesen
07.08.Black Diamond Therapeutics, Inc. - 10-Q, Quarterly Report1
07.08.Black Diamond Therapeutics, Inc. - 8-K, Current Report2
12.06.Black Diamond Therapeutics, Inc. - 8-K, Current Report2
12.05.Black Diamond Therapeutics GAAP EPS of $0.98 beats by $0.96, revenue of $70M3
12.05.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update400Clinical data on track for Q4 2025 from Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored Phase 0/1 trial into newly diagnosed glioblastoma...
► Artikel lesen
12.05.Black Diamond Therapeutics, Inc. - 8-K, Current Report1
19.03.Pre-market Movers: Leishen Energy, Black Diamond Therapeutics, FST Corp., 5E Advanced Materials, CARGO Therapeutics1.230BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Wednesday's pre-market trading (as of 08.00 A.M. ET).In the Green Leishen Energy Holding Co., Ltd. (LSE) is up over...
► Artikel lesen
19.03.Black Diamond Therapeutics, Inc: Servier and Black Diamond Therapeutics Announce Global Licensing Agreement for BDTX-4933, A Targeted Oncology Therapy302The partnership underscores Servier's commitment to developing targeted therapies that address unmet medical needs in oncologyServier will develop and commercialize BDTX-4933, a Phase 1 asset with...
► Artikel lesen
06.03.Black Diamond Therapeutics, Inc: Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update836Clinical data on track for Q2 2025 in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLCExpansion of investigator sponsored "window of opportunity" trial into newly diagnosed...
► Artikel lesen
Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1